The influence of chemotherapy on cognitive function and psychiatric symptoms in patients with breast cancer

The influence of chemotherapy on cognitive function and psychiatric symptoms in patients with breast cancer - The influence of chemotherapy on cognitive function and psychiatric symptoms in patients with breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016282

Enrollment

Registered

2015-01-20

Start date

2015-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Female patients with incipient breast cance 2) The first use of our outpatient chemotherapy room during this study

Exclusion criteria

Exclusion criteria: 1) Incapable of consent to this study 2) History of chemotherapy during admission 3) History of other malignant tumors 4) History of radiotherapy 5) Existence of brain metastasis

Design outcomes

Primary

Measure	Time frame
The primary outcomes are objective cognitive function scores in verbal fluency tasks, a part of Wechsler Memory Scale-Revised (WMS-R), Trail Making Test A/B (TMT-A/B), a part of Wechsler Adult Intelligence Scale-III (WAIS-III). We will perform them before chemotherapy (T1), within a week after the end of 1st kind chemotherapy (T2), within a week after the end of 2nd kind chemotherapy (T3), and more than 3 months after the end of 2nd kind chemotherapy (T4).	—

Measure

Time frame

The primary outcomes are objective cognitive function scores in verbal fluency tasks, a part of Wechsler Memory Scale-Revised (WMS-R), Trail Making Test A/B (TMT-A/B), a part of Wechsler Adult Intelligence Scale-III (WAIS-III). We will perform them before chemotherapy (T1), within a week after the end of 1st kind chemotherapy (T2), within a week after the end of 2nd kind chemotherapy (T3), and more than 3 months after the end of 2nd kind chemotherapy (T4).

—

Secondary

Measure	Time frame
The secondary outcomes are subjective cognitive function scores in Everyday Memory Checklist, QOL scores in Functional Assessment of Cancer Therapy-Breast (FACT-B), psychiatric symptoms scores in Hospital Anxiety and Depression Scale (HADS). We will perform them before chemotherapy (T1), within a week after the end of 1st kind chemotherapy (T2), within a week after the end of 2nd kind chemotherapy (T3), and more than 3 months after the end of 2nd kind chemotherapy (T4).	—

Measure

Time frame

The secondary outcomes are subjective cognitive function scores in Everyday Memory Checklist, QOL scores in Functional Assessment of Cancer Therapy-Breast (FACT-B), psychiatric symptoms scores in Hospital Anxiety and Depression Scale (HADS). We will perform them before chemotherapy (T1), within a week after the end of 1st kind chemotherapy (T2), within a week after the end of 2nd kind chemotherapy (T3), and more than 3 months after the end of 2nd kind chemotherapy (T4).

—

Countries

Japan

Contacts

Public ContactYukio Tada

Tokushima University Hospital Psychiatry

ytada-psy@umin.net088-631-3111

Outcome results